EGFR and colorectal carcinoma: As a result, Cetuximab and Panitumumab, monoclonal antibody biological drugs, which block binding of EGF and transforming growth factor alpha (TGF-α) to EGFR have been frequently used in chemotherapy resistant CRC patients [1,4].